Security Snapshot

Helus Pharma Inc. - Common Shares, No Par Value (HELP) Institutional Ownership

CUSIP: 23256X407

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

67

Shares (Excl. Options)

18.07MFull value: 18,070,274 · shares · 30 Sep 2026

Price

$12.29

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-6,473,539
Value change
-$14,362,056
Number of holders
67
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
76,274,034
SEC-reported price per share
$12.29
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • HELP - Helus Pharma Inc. - Common Shares, No Par Value is tracked under CUSIP 23256X407.
  • 67 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 97 to 67 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $197.56MFull value: $197,557,440 · USD · 30 Jun 2026
    to
    $222.06MFull value: $222,055,676 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 67 institutions filings for Q3 2026.

Open SEC evidence

Security key

23256X407

13F reference period

Q3 2026

13F holders

67

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
HELP
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.9% +41% $37,759,482 +$28,298,275 6,410,778 +299% Point72 Asset Management, L.P. 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 9.9% $30,106,217 5,111,412 Venrock Healthcare Capital Partners III, L.P. 31 Oct 2025
So Eric H. L. 5.8% $50,653,586 4,423,894 So Eric H. L. 01 Sep 2026
Glavine Paul 5.8% $50,465,371 4,407,456 Glavine Paul 01 Sep 2026
Adage Capital Management, L.P. 5.3% $21,807,728 3,289,250 Adage Capital Management, L.P. 30 Jun 2026
Sirenia Capital Management LP 4.8% $20,085,585 3,029,500 Sirenia Capital Management LP 30 Jun 2026
Deep Track Capital, LP 4.7% -22% $18,486,334 -$5,262,159 2,391,505 -22% Deep Track Capital, LP 31 Dec 2025
As of 30 Sep 2026, 67 institutional investors reported holding
18.07MFull value: 18,070,274 · shares · 30 Sep 2026
shares of Helus Pharma Inc. - Common Shares, No Par Value (HELP). This represents 24% of the company’s total
76.27MFull value: 76,274,034 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
21%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ADAGE CAPITAL PARTNERS GP, L.L.C. 6.9% 5,250,000 0.09% $64,522,500
ACORN CAPITAL ADVISORS, LLC 2% 1,540,266 5.2% $18,929,870
TWO SIGMA INVESTMENTS, LP 1.8% 1,339,912 0.01% $16,467,518
Point72 Asset Management, L.P. 1.6% 1,229,137 0.02% $15,106,094
DCF Advisers, LLC 1.3% 1,002,600 3.7% $12,321,954
Sio Capital Management, LLC 0.74% 561,289 1.5% $6,898,242
Integral Health Asset Management, LLC 0.66% 500,000 0.38% $6,145,000
Ikarian Capital, LLC 0.64% 487,575 1.2% $5,992,297
Y-Intercept (Hong Kong) Ltd 0.56% 424,276 0.12% $5,214,352
SPHERA FUNDS MANAGEMENT LTD. 0.51% 388,151 0.72% $4,770,376
Knott David M Jr 0.49% 370,000 2.5% $4,547,300
GREAT POINT PARTNERS LLC 0.42% 320,952 1% $3,944,500
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.38% 287,440 0.02% $3,532,638
PICTON MAHONEY ASSET MANAGEMENT 0.34% 256,593 0.03% $3,153,529
WELLINGTON MANAGEMENT GROUP LLP 0.29% 218,522 0% $2,685,635
PDT Partners, LLC 0.24% 179,797 0.12% $2,209,705
DAFNA Capital Management LLC 0.23% 175,702 0.46% $2,159,378
Jain Global LLC 0.23% 173,111 0.03% $2,127,534
NATIONAL BANK OF CANADA /FI/ 0.21% 161,134 0% $1,951,099
GROUP ONE TRADING LLC 0.21% 160,618 0.06% $1,973,995
Eversept Partners, LP 0.19% 146,056 0.1% $1,795,028
Premier Fund Managers Ltd 0.19% 144,223 0.19% $1,830,000
ACT Capital Partners, L.P. 0.18% 135,000 1.1% $1,659,150
WealthPlan Investment Management, LLC 0.14% 103,500 0.06% $1,272,015
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.12% 91,600 0% $1,125,764

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
9
Headline period
Q3 2026
Rows shown
1-9 of 9
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 18,070,274 $222,055,676 -$14,362,056 $12.29 67
2026 Q2 29,881,651 $197,557,440 +$43,217,544 $6.61 97
2026 Q1 24,099,450 $115,673,504 -$35,645,486 $4.80 78
2025 Q4 30,085,784 $246,553,227 +$165,579,566 $8.18 78
2025 Q3 9,225,298 $54,313,985 +$4,566,007 $5.89 72
2025 Q2 8,294,991 $69,584,064 +$4,016,201 $8.39 53
2025 Q1 7,827,681 $49,597,585 +$5,442,242 $6.34 53
2024 Q4 6,916,277 $61,021,460 -$124,070 $8.82 50
2024 Q3 6,189,949 $55,027,660 +$55,027,660 $8.89 40
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .